-$1.60 Earnings Per Share Expected for Agios Pharmaceuticals (AGIO) This Quarter

Analysts expect that Agios Pharmaceuticals (NASDAQ:AGIO) will post ($1.60) earnings per share (EPS) for the current quarter, Zacks reports. Three analysts have provided estimates for Agios Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.65) and the highest is ($1.54). Agios Pharmaceuticals posted earnings of ($1.56) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 2.6%. The business is expected to report its next earnings report before the market opens on Friday, May 4th.

On average, analysts expect that Agios Pharmaceuticals will report full-year earnings of ($6.25) per share for the current financial year, with EPS estimates ranging from ($6.51) to ($5.60). For the next financial year, analysts forecast that the business will post earnings of ($4.42) per share, with EPS estimates ranging from ($6.00) to ($0.01). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Agios Pharmaceuticals.

How to Become a New Pot Stock Millionaire

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.65) by ($0.16). The business had revenue of $9.80 million for the quarter, compared to analyst estimates of $12.65 million. Agios Pharmaceuticals had a negative return on equity of 76.67% and a negative net margin of 731.60%. The company’s quarterly revenue was down 56.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.34) earnings per share.

Several brokerages have recently weighed in on AGIO. Cann reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a research note on Tuesday. Oppenheimer downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 14th. They noted that the move was a valuation call. Zacks Investment Research raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $84.00 target price for the company in a research note on Tuesday, January 16th. ValuEngine raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, BidaskClub raised Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 3rd. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Agios Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $87.00.

In other news, major shareholder Corp /De/ Celgene purchased 851,154 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was purchased at an average cost of $67.00 per share, for a total transaction of $57,027,318.00. Following the completion of the transaction, the insider now owns 1,374,599 shares of the company’s stock, valued at $92,098,133. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christopher Bowden sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $78.75, for a total value of $157,500.00. Following the sale, the insider now owns 2,881 shares of the company’s stock, valued at $226,878.75. The disclosure for this sale can be found here. Insiders have sold 159,880 shares of company stock valued at $12,661,668 over the last quarter. 5.43% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Xact Kapitalforvaltning AB purchased a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth approximately $259,000. Alkeon Capital Management LLC increased its position in shares of Agios Pharmaceuticals by 12.0% during the fourth quarter. Alkeon Capital Management LLC now owns 511,619 shares of the biopharmaceutical company’s stock worth $29,250,000 after purchasing an additional 54,858 shares in the last quarter. Teachers Advisors LLC increased its position in shares of Agios Pharmaceuticals by 13.5% during the fourth quarter. Teachers Advisors LLC now owns 53,591 shares of the biopharmaceutical company’s stock worth $3,064,000 after purchasing an additional 6,375 shares in the last quarter. HBK Investments L P purchased a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth approximately $306,000. Finally, Two Sigma Investments LP increased its position in shares of Agios Pharmaceuticals by 18.8% during the fourth quarter. Two Sigma Investments LP now owns 53,265 shares of the biopharmaceutical company’s stock worth $3,045,000 after purchasing an additional 8,434 shares in the last quarter. Hedge funds and other institutional investors own 82.41% of the company’s stock.

Shares of AGIO stock traded up $0.99 during trading hours on Thursday, hitting $87.01. 255,053 shares of the company’s stock were exchanged, compared to its average volume of 590,903. The company has a market cap of $5,006.34, a price-to-earnings ratio of -12.91 and a beta of 1.98. Agios Pharmaceuticals has a fifty-two week low of $45.11 and a fifty-two week high of $89.33.

WARNING: This article was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://sportsperspectives.com/2018/04/17/1-60-earnings-per-share-expected-for-agios-pharmaceuticals-agio-this-quarter.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply